Most Read Articles
01 Aug 2016
Metronomic cyclophosphamide is modestly effective, and may be a safe and non-expensive treatment alternative in hormone-naïve patients with non-metastatic biochemical recurrent prostate cancer, as stated in a prospective single-arm open-label phase II study.

Idiopathic Parkinson’s disease ups risk of overactive bladder

12 Mar 2018

Patients with idiopathic Parkinson’s disease (IPD) appear to be at a higher risk of overactive bladder (OAB), a recent study has shown.

Accessing the National Health Insurance Research Database of Taiwan, the researchers identified 4,571 IPD patients and 18,255 non-IPD controls, in whom the occurrence of OAB was evaluated. Cox proportional hazard regression models were used to assess the risk of OAB.

In the IPD cohort, the incidence rate of OAB was calculated to be 14.5 per 10,000 person-years, higher than the 6.37 per 10,00 person-years in the control group. The risk of OAB was significantly higher in the IPD group (hazard ratio [HR], 2.31; 95 percent CI, 1.51–3.52; p<0.001).

The risk elevation remained statistically significant even after multivariate adjustments (HR, 2.30; 1.51–3.51; p<0.001).

When stratifying patients according to comorbidities, the researchers showed that the risk of OAB was significantly elevated in IPD patients with benign prostate hyperplasia (HR, 2.94; 1.66–5.18; p<0.001) and stress incontinence (HR, 3.44; 1.09–10.9; p<0.05).

Kaplan-Meier curves were constructed to determine the cumulative incidence of OAB in both cohorts. The results were significantly higher in the IPD group than in the control cohort after 12 years of follow-up (p<0.001).

The present study shows that there is a correlation between higher OAB risk and IPD. Future studies should then focus on establishing a causal link between the two, according to the researchers.

Editor's Recommendations
Most Read Articles
01 Aug 2016
Metronomic cyclophosphamide is modestly effective, and may be a safe and non-expensive treatment alternative in hormone-naïve patients with non-metastatic biochemical recurrent prostate cancer, as stated in a prospective single-arm open-label phase II study.